Talphera (NASDAQ:TLPH) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Talphera (NASDAQ:TLPH) in a report released on Tuesday,Benzinga reports. HC Wainwright currently has a $6.00 price target on the stock.

A number of other equities analysts also recently issued reports on the company. Rodman & Renshaw started coverage on Talphera in a research report on Tuesday, January 28th. They set a “buy” rating and a $4.00 price target on the stock. RODMAN&RENSHAW upgraded shares of Talphera to a “strong-buy” rating in a report on Tuesday, January 28th.

Talphera Price Performance

Shares of TLPH stock opened at $0.53 on Tuesday. The company has a market capitalization of $9.03 million, a P/E ratio of -0.77 and a beta of 0.20. The company’s 50-day simple moving average is $0.61 and its two-hundred day simple moving average is $0.71. Talphera has a one year low of $0.45 and a one year high of $1.27.

Talphera (NASDAQ:TLPH) last announced its quarterly earnings data on Monday, March 31st. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.14. On average, research analysts expect that Talphera will post -0.64 EPS for the current fiscal year.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.